The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
An excellent RNS imo. Besides the upbeat content highlighted by many posters here it is also an example of 'unexpected news'. As is the case with affimers we are likely to receive all kinds of 'tangential news' regarding previously unforeseen applications. The example in the RNS builds on a known application taken to a new level but there will be many other opportunities to come. Regarding the SP, the RNS might not have dropped along with that unmistakable stench of burning shorts but it does have all the attributes of a match having been lit :-) VGLA
Although the sp response to this good news is underwhelming, what it does though is give the sp a solid support level. Only way is up from here, sentiment is turning, but the market still obsessed with LFT news.
Todays RNS brings in focus the market worth:
preCISION can be widely applied to a range of other chemotherapies in a market worth $56.5B
This is what todays RNS is about. Potential for a pipeline of pre|CISION pro-drugs, some of which have already been synthesized, with an addressable market of many $bn pa.
Including but not limited to:
• Pre|CISION pro-proteasome inhibitor
• Pre|CISION Paclitaxel
• Pre|CISION Oxaliplatin
• Pre|CISION Gemcitabine
• Pre|CISION Capecitabine
• Pre|CISION PARP inhibitor
• Pre|CISION PD-1 Inhibitor
• Pre|CISION AKT inhibitor
• Pre|CISION Balixafortide
@JDF7 as you are aware and so are those who are investing in Avacta, this is a platform technology. The preCISION chemistry validation will imply multiple drugs will become part of the Avacta pro-drug line up. That in itself is the value driver at this point in time.
Radiagreen, the market knows a thing or two about the challenges and risks of phase 1, phase 2 and phase 3 trials and then about the multiple uncertainties around the authorisation processes of bodies like the FDA. Identifying a candidate drug for phase 1 trial doesn't mean it is a winner. If it gets to phase 2 trials and meets whatever end-points to prove clinical , statistically significant efficacy in a large trial group, then the market may start to look up ahead of phase 3 trials. That is a long way away but for those who have a high risk-appetite maybe putting down a large wad on this RNS feels okay. Each to their own.
It's all a matter of perspective here. The larger institutional or private stakeholders will be watching preCISION very carefully. Todays news provides for me the biggest indication of what AVA6000 results will be and creates the room/time to deploy capital as necessary.
Expecting some order filling very soon.
Lots more interested in getting the lft back on the market
And sales
Shocking
This rns is massive but to long term for some
All very blinkered
Surprising market reaction.
A very positive rns, an indicator of good results for ph1a! However what the market really needs is for this to be spelt out, fully expecting a Av6000 ph 1a update very shortly, probably this week.
AVA3996 has shown excellent promise following "efficacy studies in several liquid and solid tumour models, safety studies".
It is the second prodrug entering the pipeline and endorses pre|Cision and the first prodrug AVA6000.
That's a very good point marik.
Just to put some perspective on this, Avacta are progressing with the "first proteasome inhibitor to be suitable for treating solid tumours". This is described by EVERYONE in the industry as "the holy grail".
We've just had news "**Second** pre|CISION Pro-drug Candidate Selected", that also endorses the current dose escalation preCISION drug AVA6000.
That's a very strong RNS.
Ripley wasn't on the Rome job
This RNS is further validation of the promise shown by Avactas tech. Obviously, still a lot of work do be done, but then Rome wasn't built in a day etc etc
Pan galactic gargle blasters all round.
There's only one (self confessed) twat on here day in day out actually.
Ah but according to alwayswinning 99.9% of us aren't interested in this news
We've just received possibly one of the most pivotal RNS for the company - i.e. the platform that Avacta are using works.
Prognosis with those with multiple myeloma is just over 50%, the chemotherapy for which is extremely toxic. AVA3996 will be "the first proteasome inhibitor to be suitable for treating solid tumours, thereby significantly increasing the market opportunity".
That's a resounding yes to AVA6000 and preCision.
Yes live and learn, they’ve spend a lot of time and money on this but below just to keep the PIs happy. They thought eh lads and ladies, shall we collate all manner of pre clinical data and release an RNS because some covid investors aren’t happy? I know this is the bread and butter of the company and it’s what the majority of the placing was intended for but you know…..
“Following a review of efficacy studies in several liquid and solid tumour models……..”
You’ve got to be an intentional twat to think this has anything to do with improving sentiment. It’s the core of Avacta business. It’s also a very strong indicator AVA6000 is going extremely well.
I see the special bus brigade are up early. Don’t feed them. It’s good news, it’s further validation of the tech, it suggests all is well with AVA. Nice to see.
Any LTH’s will be willing for a SP drop here , to load up again. Prefer to keep quiet about this news !!
Obviously great to see some positive news and this will become a huge milestone should it progress, however, it is clearly an attempt to stop the declining share price
Great news. Just watch the SP drop by close of play today….
@poirot it is huge news. preCision platform is working! AVA6000 must be doing well otherwise they wouldn't push ahead with this. I'm not surprised that Trinity Delta put such high price tag on the Tx.
Obviously good news but let's not get carried away. If Kong is correct with his forecast it'll just be the opportunity to carry out some sensible portfolio management and reduce risk for many. I think a bump of 10% would probably be more realistic.